The patent links reduced tail saturation, the 2DC18 ketone and ethyl isocyanoacetate substructure with improved delivery across the broader lipidoid library; these are library-level observations and not A12-only causal tests.
· WO2020047399A1 [00262]-[00263].sales@dcchemicals.com
A12-Iso5-2DC18
Formulation & Performance
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| A12-Iso5-2DC18 | 35 | Ionizable lipid |
| DOPE | 16 | Helper phospholipid |
| Cholesterol | 37.5 | Sterol |
| C14-PEG | 2.5 | PEG lipid |
| Reported total | 91 | Source values retained |
Formulation calculator unavailable. The A2 model ratio is retained as reported for context only. A12-specific helper-lipid identity, PEG molecular weight and exact optimized ratio are not sufficiently resolved for a fixed calculator. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reportedA12 and A2 induced similar levels of protein expression in local tissue and draining lymph nodes and transfected macrophage/monocyte and dendritic-cell populations.mLuc or Cre mRNA LNPs in mice · A2 LNPsWO2020047399A1 [00266], Figures 3B-3G and 12.
Literature-reportedA12 mOVA LNPs produced lower CTL and IFN-gamma responses than A2 mOVA LNPs in the cited comparison.mOVA vaccination · A2 mOVA LNPsWO2020047399A1 [00267], Figures 3H and 13.
Literature-reportedA12 mOVA LNPs showed almost no anti-tumor efficacy in the B16F10-OVA model under the reported conditions.Two-dose mOVA vaccination, once every five days · A2 mOVA LNPsWO2020047399A1 [00267]-[00268], Figure 3I.
Literature-reportedBoth A2 and A12 were identified as high-performing 2DC18/ethyl-isocyanoacetate lipidoids and were approximately two-fold higher than Dlin-KC3-DMA in the cited comparison.In-vitro and in-vivo screening · Dlin-KC3-DMAWO2020047399A1 [00263].
Additional reported findings
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetMiao L, Li L, Anderson DG, Huang Y. Ionizable lipidoids and their uses. WO2020047399A1, 2020. DOI: https://patents.google.com/patent/WO2020047399A1/en
All quantitative and biological claims apply to the patent's reported A12/A2 LNP study conditions, not to the neat lipid alone.
All quantitative and biological claims apply to the patent's reported A12/A2 LNP study conditions, not to the neat lipid alone.